Skip to main content

Moderna Inc (MRNA) Stock

Moderna Inc Stock Details, Movements and Public Alerts

Stock Details

Moderna Inc (MRNA), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $24.77. Over the past 52 weeks, it has ranged between $23.04 and $48.92. This places the current price at 50.6% of its 52-week high and 7.5% above its 52-week low. Recent trading volume was recorded at 933. The 14-day Relative Strength Index (RSI) stands at 45.59, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $25.92 by 4.44%. Similarly, it is below its 200-day moving average of $28.30 by 12.47%. The MACD histogram is -0.02, indicating bearish momentum (MACD Line: -0.35, Signal Line: -0.33). The International Securities Identification Number (ISIN) for this stock is US60770K1079. There is currently 1 active alert set for MRNA by users.

52-Week Range

$48.92 - $23.04

-49.37% from high · +7.51% from low

Avg Daily Volume

12,243,781

20-day average

100-day avg: 10,564,741

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

32.47

PEG Ratio

0.00

Potentially undervalued

Price to Book

1.12

EV/EBITDA

4.64

EPS (TTM)

-$8.06

Price to Sales

4.37

Beta

1.11

Similar volatility to market

How is MRNA valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is MRNA's risk profile compared to the market?
With a beta of 1.11, Moderna Inc is roughly as volatile as the market, moving in line with broad market trends. This moderate beta suggests the stock offers market-level returns without excessive volatility. The price-to-book ratio of 1.12 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-139.60%

Operating Margin

-25.60%

EBITDA

$-3,255,000,064

Return on Equity

-29.30%

Return on Assets

-15.50%

Revenue Growth (YoY)

-45.40%

Earnings Growth (YoY)

-85.10%

How profitable and efficient is MRNA's business model?
Moderna Inc achieves a profit margin of -139.60%, meaning it retains $-139.60 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -25.60% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -29.30% and ROA at -15.50%, the company achieves moderate returns on invested capital.
What are MRNA's recent growth trends?
Moderna Inc's revenue declined by 45.40% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 85.10% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$9.8B

Revenue (TTM)

$2.23B

Revenue/Share (TTM)

$5.76

Shares Outstanding

390.68M

Book Value/Share

$23.86

Asset Type

Common Stock

What is MRNA's market capitalization and position?
Moderna Inc has a market capitalization of $9.8B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 390.68M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does MRNA's price compare to its book value?
Moderna Inc's book value per share is $23.86, while the current stock price is $24.77, resulting in a price-to-book (P/B) ratio of 1.04. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$39.15

58.05% upside potential

Analyst Recommendations

Strong Buy

2

Buy

3

Hold

15

Sell

1

Strong Sell

3

How reliable are analyst predictions for MRNA?
24 analysts cover MRNA with 21% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $39.15 implies 58.1% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on MRNA?
Current analyst recommendations:2 Strong Buy, 3 Buy, 15 Hold, 1 Sell, 3 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Nov 15, 2025, 02:03 AM

Technical Indicators

RSI (14-day)

45.59

Neutral

50-Day Moving Average

$25.92

-4.44% below MA-50

200-Day Moving Average

$28.30

-12.47% below MA-200

MACD Line

-0.35

MACD Signal

-0.33

MACD Histogram

-0.02

Bearish

What does MRNA's RSI value tell investors?
The RSI (Relative Strength Index) for MRNA is currently 45.59, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
How should traders interpret MRNA's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.35 below the signal line at -0.33, with histogram at -0.02. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($25.92) is below the 200-day MA ($28.30), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Nov 17, 2025, 12:45 AM

Active Alerts

Alert Condition
Forward P/E falls below
Threshold
28 x
Created
Nov 4, 2025, 04:37 PM

Stay Ahead of the Market with Moderna Inc Alerts

Set up price alerts for Moderna Inc and get notified instantly when the price hits your target. Never miss an important price movement again.